Company Encyclopedia
View More
name
AVE
688067.SH
AVE Science&Technology CO.,LTD researches, develops, manufactures, markets, and services medical devices, biological reagents, remote medical diagnosis network, computer software, automatic control devices, and medical auxiliary equipment. The company’s products include urine formed elements analyzer and related reagents, automatic urine analyzers, multi-function microscopy analyzers, semi-automatic biochemical analyzers, feces analyzers, and vaginal secretions analyzers; and reagents and consumables comprising reagent packs, test strips, urine analyzer cleansers, urine sample collectors, and urine formed elements analyzer’s quality control products. It serves customers in Europe, the United States, Asia, Africa, and internationally. The company was founded in 2000 and is headquartered in Changsha, China.
883.73 B
688067.SHMarket value -Rank by Market Cap -/-

Financial Score

22/11/2025 Update
B
Health Care EquipmentIndustry
Industry Ranking27/63
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE5.30%C
    • Profit Margin12.19%B
    • Gross Margin59.38%A
  • Growth ScoreB
    • Revenue YoY9.11%B
    • Net Profit YoY19.46%B
    • Total Assets YoY10.46%B
    • Net Assets YoY3.77%C
  • Cash ScoreB
    • Cash Flow Margin820.50%B
    • OCF YoY9.11%B
  • Operating ScoreC
    • Turnover0.38C
  • Debt ScoreA
    • Gearing Ratio15.22%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    AVE released its performance for the first three quarters, with a net profit attributable to the parent company of 29.24 million yuan, a year-on-year increase of 16.35%

    According to the Zhitong Finance APP, AVE disclosed its third-quarter report for 2025. The company achieved revenue of 171 million yuan in the first three quarters, a year-on-year increase of 11.63%; net profit attributable to the parent company was 29.24 million yuan, a year-on-year increase of 16.35%; net profit excluding non-recurring gains and losses was 25.25 million yuan, a year-on-year increase of 24.92%; basic earnings per share were 0.43 yuan

    Zhitong·
    SH
    688067
    -4.65%
    Zhitong·
    SH
    688067
    -4.65%

    AVE plans to increase its investment in Luying Technology by 10 million yuan, with its core products being SPECT and SPECT/CT and their core components

    AVE announced plans to increase its investment in Luying Technology by 10 million yuan using its own funds. After the investment, it will hold a 9.0744% stake in Luying Technology. Luying Technology focuses on the development of domestically produced high-resolution single-photon emission computed tomography (SPECT) and its core components, providing precise, safe, economical, and convenient molecular imaging diagnostic technology solutions

    Zhitong·
    SH
    688067
    -4.65%
    Zhitong·
    SH
    688067
    -4.65%

    AVE: Establishing Hunan AVE Optical Technology Co., Ltd., with a registered capital of 10 million yuan

    AVE announced that the company, together with Changsha Kudan, has jointly invested to establish Hunan AVE Optical Technology Co., Ltd. AVE Optical has a registered capital of RMB 10 million, of which the company contributes RMB 6 million in its own funds, accounting for 60% of the registered capital of AVE Optical; Changsha Kudan contributes RMB 4 million in intellectual property, accounting for 40% of the registered capital of AVE Optical

    Zhitong·
    SH
    688067
    -4.65%
    Zhitong·
    SH
    688067
    -4.65%

    AVE: Establishing a holding subsidiary Aiwei Zhijian with a registered capital of 10 million yuan

    AVE and Wang Jianzhong jointly invested to establish Beijing Aiwei Zhijian Diagnostic Technology Co., Ltd., with a registered capital of 10 million yuan. AVE contributed 6 million yuan, accounting for 60% of the shares; Wang Jianzhong contributed 4 million yuan in intellectual property, accounting for 40% of the shares. The company completed its business registration and obtained a business license on August 28, 2025

    Zhitong·
    SH
    688067
    -4.65%
    Zhitong·
    SH
    688067
    -4.65%

    AVE released its semi-annual performance, with a net profit attributable to the parent company of 14.06 million yuan, a year-on-year increase of 21.16%

    According to the Zhitong Finance APP, AVE disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 110 million yuan, a year-on-year increase of 12.70%; net profit attributable to the parent company was 14.06 million yuan, a year-on-year increase of 21.16%; net profit excluding non-recurring gains and losses was 11.38 million yuan, a year-on-year increase of 37.24%; basic earnings per share were 0.21 yuan

    Zhitong·
    SH
    688067
    -4.65%
    Zhitong·
    SH
    688067
    -4.65%